Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 15–16

HOS-112086 · Präparat HOS-093615

15 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ACID REDUCING AGENTS H2-Receptor antagonists Without Tenofovir In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking tenofovir, dose 300/100 mg once daily if REYATAZ 300 mg/ritonavir Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 100 mg and H2-receptor antagonists Atazanavir Cmax: ↓20% (↓32% ↓7%) are co-administered, a dose Atazanavir Cmin: ↔1% (↓16% ↑18%) equivalent to famotidine 20 mg twice daily should not be exceeded. Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) If a higher dose of an H2-receptor Atazanavir Cmax: ↓23% (↓33% ↓12%) antagonist is required (e.g., Atazanavir Cmin: ↓20% (↓31% ↓8%) famotidine 40 mg twice daily or In healthy volunteers with atazanavir/ritonavir at an increased dose equivalent) an increase of the of 400/100 mg once daily REYATAZ/ritonavir dose from Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) 300/100 mg to 400/100 mg can be Atazanavir Cmax: ↔2% (↓13% ↑8%) considered. Atazanavir Cmin: ↓14% (↓32% ↑8%) With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil) In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking of 300/100 mg once daily tenofovir disoproxil fumarate, if Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* REYATAZ/ritonavir with both Atazanavir Cmax: ↓21% (↓36% ↓4%)* tenofovir disoproxil fumarate and Atazanavir Cmin: ↓19% (↓37% ↑5%)* an H2-receptor antagonist are co- administered, a dose increase of Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* REYATAZ to 400 mg with 100 mg Atazanavir Cmax: ↓23% (↓36% ↓8%)* of ritonavir is recommended. A Atazanavir Cmin: ↓25% (↓47% ↑7%)* dose equivalent to famotidine In HIV-infected patients with atazanavir/ritonavir at an increased dose 40 mg twice daily should not be of 400/100 mg once daily exceeded. Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)* Atazanavir Cmax: ↑18% (↑6.7% ↑31%)* Atazanavir Cmin: ↑24% (↑10% ↑39%)* Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)* Atazanavir Cmax: ↔5% (↓17% ↑8.4%)* Atazanavir Cmin: ↔1.3% (↓10% ↑15)* *When compared to atazanavir 300 mg once daily with ritonavir 100 mg once daily and tenofovir disoproxil fumarate 300 mg all as a single dose with food. When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil fumarate, atazanavir concentrations are expected to be additionally decreased by about 20%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)